VIEWRAY, INC. (NASDAQ:VRAY) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On October9, 2017, ViewRay Technologies, Inc., a wholly-owned subsidiary of ViewRay, Inc. (the “Company”), entered into Amendment No.3 to the Term Loan Agreement (the “Amendment”) with Capital Royalty Partners II L.P., Capital Royalty Partners II (Cayman) L.P., Parallel Investment Opportunities Partners II L.P. and CRG Issuer 2015-1 (collectively, the “Lenders”).
to the Amendment, the Company and the Lenders agreed, among other things, to extend the commitment period during which the Company can borrow loans under the term loan facility to the earlier of (a)December 31, 2017 and (b)the date on which the Company provides written notice of termination of the commitment period.
The foregoing description is only a summary and is qualified in its entirety by reference to the Amendment, a copy of which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ended September30, 2017.
About VIEWRAY, INC. (NASDAQ:VRAY)
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
